According to a new study of Savella (milnacipran) for the treatment of fibromyalgia, patients who continue treatment can get long-term pain relief – to at least three years. These findings were reported by Lesley Arnold, MD, professor of psychiatry at the University of Cincinnati College of Medicine in a poster presentation at the recent annual meeting of the American College of Rheumatology. Savella , the third drug to be approved for treating fibromyalgia, received its FDA approval in January 2009. This is the first study showing its long-term efficacy. Study Design and Results This was a four-phase clinical trial that originally included 1,268 patients. Similar relief was achieved by the 820 who took Savella for one year, the 462 who completed two years and the 217 who continued for three years. In the original group, 1,212 patients achieved a mean decrease of 17.6 points in their Visual Analogue Pain Weekly Recall, or Visual Analogue Scale (...
There are many different reasons you may decide to stop taking ADHD medications or determine that you want to have your child take a " medication break ." Some of the reasons people stop taking ADHD medications:
You want to try controlling symptoms through alternative methods
You want to know if you still need medications
You have developed a medical condition and the medication will interfere with treatment
You are, or want to become, pregnant
You don't want to take medication for the rest of your life
You are a teen and want to stop taking medication
Whatever the reason, should you decide to stop the medication, either short-term or long-term, there are some things you should be aware of. Withdrawal Symptoms While most people are able to stop their medication without feeling any withdrawal symptoms, some people do experience symptoms. The main symptoms you may feel are:
Unusual behavior ( Ritalin, Concerta and other methylphenidate based...
It has long been thought that Cymbalta (generic name duloxetine) would be the second medication to receive FDA approval for the treatment of fibromyalgia . However, the disappointing results of the third phase III efficacy study could stall Lilly’s quest for approval. The 27-week phase III clinical trial randomized 330 fibromyalgia patients to either a 60 mg or 120 mg per day dose or to a placebo. Patients were allowed to switch between the 60 and 120 mg dosages during the study according to efficacy and tolerability. Study Results Cymbalta failed to achieve a statistically significant difference over the placebo in the primary outcome measures. The mean reduction in pain severity (measured by the Brief Pain Inventory) was 1.62 for Cymbalta and 1.12 for the placebo. The patients’ impressions of improvement scores averaged 3.42 for Cymbalta and 3.73 for the placebo. Cymbalta also showed no significant improvement in physical function. This study stands in stark contr...
You should knowAnswers to your question are meant to provide general health information but should not replace medical advice you receive from a doctor. No answers should be viewed as a diagnosis or recommended treatment for a condition. Content posted by community members does not necessarily reflect the views of Remedy Health Media, which also reserves the right to remove material deemed inappropriate.